Author:
Martins Cláudia,Sarmento Bruno
Reference44 articles.
1. Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8(8):2086–2095.
https://doi.org/10.1158/1535-7163.Mct-09-0366
2. Gligorov J, Lotz JP (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 9(Suppl 2):3–8
3. Elhissi A, Mahmood R, Parveen I, Vali A, Ahmed W, Jackson MJ (2018) Taxane formulations: from plant to clinic. In: Jackson MJ, Ahmed W (eds) Micro and nanomanufacturing volume II. Springer, Cham, pp 23–33.
https://doi.org/10.1007/978-3-319-67132-1_2
4. Yared JA, Tkaczuk KHR (2012) Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 6:371–384.
https://doi.org/10.2147/DDDT.S28997
5. Harrison MR, Holen KD, Liu G (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7(1):54–64
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献